Mesa Laboratories Inc: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 6, 2020 and accepted by EDGAR at Aug 6, 2020, 08:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $29.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $10.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-04-01 to 2020-06-30 | $20.0m | us-gaap:GrossProfit |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | $3.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-04-01 to 2020-06-30 | $1.9m | us-gaap:InterestExpense |
| Income tax | 3 months2020-04-01 to 2020-06-30 | −$643.0k | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | $0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-04-01 to 2020-06-30 | $0.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 4,669,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2020-04-01 to 2020-06-30 | $2.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-04-01 to 2020-06-30 | $216.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2020-04-01 to 2020-06-30 | $704.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2020-06-30 | $231.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $269.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $576.7m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $20.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $194.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $382.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-20-016748. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.